Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.44)
# 4,248
Out of 5,099 analysts
16
Total ratings
28.57%
Success rate
-17.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.55 | +445.45% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $2.10 | +661.90% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $3.99 | +125.56% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.71 | +115.63% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $20.25 | +393.83% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $2.09 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.31 | +48,427.98% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $1.75 | +757.14% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $6.12 | +243.14% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $78.22 | +15.06% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.57 | +11,962.26% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $2.90 | +1,158,520.69% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.55
Upside: +445.45%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $2.10
Upside: +661.90%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $3.99
Upside: +125.56%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.71
Upside: +115.63%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $20.25
Upside: +393.83%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.09
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.31
Upside: +48,427.98%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $1.75
Upside: +757.14%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $6.12
Upside: +243.14%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $78.22
Upside: +15.06%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.57
Upside: +11,962.26%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $2.90
Upside: +1,158,520.69%